PRELIMINARY NOTE The unaudited half-year consolidated Financial Statements included herein have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Account

The unaudited half-year consolidated Financial Statements included herein have been prepared in accordance with

International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ). The consolidated financial statements are presented in euros. All references in this interim report to

$, US$, U.S.$, U.S. dollars, dollars, and USD mean U.S. dollars and all references to and euros mean euros, unless otherwise noted.

This interim report, including Management s Discussion and Analysis of Financial Condition and Results of

Operations, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act. All statements other than present and historical facts and conditions

contained in this interim report, including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this interim

report, the words anticipate, believe, can, could, estimate, expect, intend, is designed to, may, might, plan,

potential, predict, objective, should, or the negative of these and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those

projected in any forward-looking statement. Factors that may cause actual results to differ from those in any forward-looking statement include, without limitation, those described under Risk Factors and Special Note Regarding

Forward-Looking Statements in our Registration Statement on Form F-1 (File No. 333-202205) filed with the Securities and Exchange Commission on March 24, 2015 (the Registration Statement ). As a result of these factors, we

cannot assure you that the forward-looking statements in this interim report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties

in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to

publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

As used in this interim report, the terms Cellectis, we, our, us, and

the Company refer to Cellectis S.A. and its subsidiaries, taken as a whole, unless the context otherwise requires.

UNAUDITED INTERIM STATEMENTS OF CONSOLIDATED FINANCIAL POSITION

The accompanying notes form an integral part of these unaudited interim condensed Consolidated Financial

UNAUDITED INTERIM STATEMENTS OF CONSOLIDATED OPERATIONS

For the six months ended June 30

in thousands, except per share amounts

The accompanying notes form an integral part of these unaudited interim condensed Consolidated Financial

UNAUDITED INTERIM STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS

For the six months ended June 30

The accompanying notes form an integral part of these unaudited interim condensed Consolidated Financial

UNAUDITED INTERIM STATEMENTS OF CONSOLIDATED CASH FLOWS

For the six months ended June 30 ( in thousands)

The accompanying notes form an integral part of these unaudited interim condensed Consolidated Financial

UNAUDITED INTERIM STATEMENTS OF CHANGES IN CONSOLIDATED SHAREHOLDERS EQUITY

For the six months ended June 30

in thousands, except share data

Please refer to Note 3 relating to the repurchase of minority shareholders of Cellectis Bioresearch.

The accompanying notes form an integral part of these unaudited interim condensed Consolidated Financial Statements

NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Cellectis S.A. (hereinafter Cellectis or we ) is a limited liability company

( soci t anonyme ) registered and domiciled in Paris, France. We are a gene-editing company, employing our core proprietary technologies to develop products in the emerging field of immuno-oncology. Our product candidates,

based on gene-edited T-cells that express chimeric antigen receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers. Our gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are

derived from healthy donors rather than the patients themselves. In addition to our focus on immuno-oncology, we are exploring the use of our gene-editing technologies in other therapeutic applications, as well as to develop healthier food products

for a growing population.

We view our operations and manage our business in two operating and reportable segments that

are engaged in the following activities: (1) Therapeutics, which is focused on the development of products in the field of immuno-oncology and of novel therapies outside immuno-oncology to treat other human diseases; (2) Plants, which is

focused on the development of new generation plant products in the field of agricultural biotechnology on our own or through alliances with other companies in the agricultural industry.

Note 2. Basis of presentation and statement of compliance

All financial information (unless indicated otherwise) is presented in thousands of euros.

2.1 Compliance with the IFRS accounting framework

The half-year Consolidated Financial Statements have been prepared in accordance with International Financial Reporting

Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ), whose application is mandatory for the half year ended June 30, 2015.

These half year Consolidated Financial Statements as of June 30, 2015 were approved by our Board of Directors on

IFRS include International Financial Reporting Standards ( IFRS ), International

Accounting Standards ( the IAS ), as well as the interpretations issued by the Standards Interpretation Committee ( the SIC ), and the International Financial Reporting Interpretations Committee ( IFRIC ).

The Interim [Condensed] Consolidated Financial Statements for the six months ended June 30, 2015 have been prepared using

the same accounting policies and methods as those applied for the year ended December 31, 2014.

2.2 Application of new or

amended standards or new amendments

The following pronouncements and related amendments have been adopted by us

from January 1, 2015 but had no significant impact on the half-year Consolidated Financial Statements:

2.3 Standards, interpretations and amendments issued but not yet effective

The following pronouncements and related amendments are applicable for half-year accounting periods beginning after

January 1, 2016. We do not anticipate that the adoption of these pronouncements and amendments will have a material impact on our results of operations, financial position or cash flows.

IFRS 15 Revenue from Contracts with Customers establishes a comprehensive framework for determining whether, how much and when

revenue is recognized. It replaces existing revenue recognition guidance, including IAS 18 Revenue. IFRS 15 is effective for annual reporting periods beginning on or after January 1, 2017, with early adoption permitted. We are assessing the

potential impact on our Consolidated Financial Statements resulting from the application of IFRS 15.

Note 3. Consolidated entities

Our 2015 half year Consolidated Financial Statements include the operations of Cellectis S.A.; our two French

subsidiaries, Cellectis Bioresearch and Ectycell; our three U.S. subsidiaries, Calyxt, Inc. (formerly Cellectis Plant Sciences Inc.), Cellectis, Inc. and Cellectis Bioresearch Inc. Cellectis, Inc. houses our U.S. headquarters and U.S. research

department, and it has been in operation since April 2015. On May 18, 2015, we signed with the Caisse des D p ts et Consignations a contract for our repurchase of its participation in Cellectis Bioresearch, which

represented 25% of the total shares thereof. As of June 30, 2015, Cellectis S.A. was the sole stockholder of Cellectis Bioresearch. This transaction with Caisse des D p ts et Consignations had an impact on the Company s

shareholders equity, which decreased by 3.5 million.

Our 2014 annual Consolidated Financial Statements

included the operations of Cellectis S.A.; our two French subsidiaries, Cellectis Bioresearch and Ectycell; our two U.S. subsidiaries, Cellectis Plant Sciences Inc. and Cellectis Bioresearch Inc.; and our former Swedish subsidiary, Cellectis AB.

On June 30, 2014, our former subsidiary, Cellectis Therapeutics, was merged into, and absorbed by, Cellectis S.A. On

August 29, 2014, we finalized the sale of Cellectis AB.

Note 4. Reportable segments

The Chief Operating Decision Maker ( CODM ) assesses the performance of the Company s segments using information

about their revenues and operating profit or loss. The CODM does not review any asset or liability information by segment or by region. For the half-year ended June 30, 2014, the CODM viewed the business in two reportable

segments Therapeutics and Plants.

For prior periods, the CODM assessed the performance of three

segments Therapeutics, Plants and Tools and Services. However, following the sale of Cellectis AB in August 2014, the Tools and Services segment was managed as a discontinued activity, and the segment information presented for prior periods,

including the half-year ended June 30, 2014, has been retrospectively restated to present two operating and reporting segments, with Tools and Services activities included within Therapeutics for comparison purposes.

Our corporate expenses and certain research activities are managed at the parent-company level by Cellectis S.A., whose

operations are presented entirely in the Therapeutics segment. There are intersegment transactions between the two reportable segments, including allocation of corporate general and administrative expenses by Cellectis S.A. to its subsidiaries and

allocation of research and development expenses and selling, general and administrative expenses to the reportable segments. Information related to each reportable segment is set out below. Segment revenue and operating profit or loss are used to

measure performance.

The operating profit or loss includes the impact of the operations between segments while the

intra-segment operations are eliminated. The segment information presented below excludes amounts related to Cellectis AB, which was classified as a discontinued operation for the half year ended June 30, 2014.

Amounts above do not include amounts for Cellectis AB, which is presented as discontinued

Note 5. Impairment tests

Our cash-generating units ( CGUs ) correspond to the operating/reportable segments: Therapeutics and Plants. No

indicator of impairment has been identified for either of the CGUs for the six-month period ending June 30, 2015.

Property, plant and equipment

Increases are notably related to investments in our new U.S. headquarters and in R&D

equipment in both the United States and France.